These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R; Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361 [TBL] [Abstract][Full Text] [Related]
8. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study. Bockstal V; Shukarev G; McLean C; Goldstein N; Bart S; Gaddah A; Anumenden D; Stoop JN; Marit de Groot A; Pau MG; Hendriks J; De Rosa SC; Cohen KW; McElrath MJ; Callendret B; Luhn K; Douoguih M; Robinson C PLoS One; 2022; 17(10):e0274906. PubMed ID: 36197845 [TBL] [Abstract][Full Text] [Related]
9. A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. Joseph S; Quinn K; Greenwood A; Cope AV; McKay PF; Hayes PJ; Kopycinski JT; Gilmour J; Miller AN; Geldmacher C; Nadai Y; Ahmed MI; Montefiori DC; Dally L; Bouliotis G; Lewis DJ; Tatoud R; Wagner R; Esteban M; Shattock RJ; McCormack S; Weber J Front Immunol; 2017; 8():149. PubMed ID: 28275375 [TBL] [Abstract][Full Text] [Related]
10. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial. Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679 [TBL] [Abstract][Full Text] [Related]
11. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. Churchyard G; Mlisana K; Karuna S; Williamson AL; Williamson C; Morris L; Tomaras GD; De Rosa SC; Gilbert PB; Gu N; Yu C; Mkhize NN; Hermanus T; Allen M; Pensiero M; Barnett SW; Gray G; Bekker LG; Montefiori DC; Kublin J; Corey L PLoS One; 2016; 11(9):e0161753. PubMed ID: 27583368 [TBL] [Abstract][Full Text] [Related]
12. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D; Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962 [TBL] [Abstract][Full Text] [Related]
14. Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model. Dzhivhuho GA; Rehrl SA; Ndlovu H; Horsnell WGC; Brombacher F; Williamson AL; Chege GK PLoS Pathog; 2018 Jul; 14(7):e1007182. PubMed ID: 30048550 [TBL] [Abstract][Full Text] [Related]
15. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. Mutua G; Anzala O; Luhn K; Robinson C; Bockstal V; Anumendem D; Douoguih M J Infect Dis; 2019 Jun; 220(1):57-67. PubMed ID: 30796816 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda. Man-Lik Choi E; Abu-Baker Mustapher G; Omosa-Manyonyi G; Foster J; Anywaine Z; Musila Mutua M; Ayieko P; Vudriko T; Ann Mwangi I; Njie Y; Ayoub K; Mundia Muriuki M; Kasonia K; Edward Connor N; Florence N; Manno D; Katwere M; McLean C; Gaddah A; Luhn K; Lowe B; Greenwood B; Robinson C; Anzala O; Kaleebu P; Watson-Jones D; Vaccine; 2023 Dec; 41(50):7573-7580. PubMed ID: 37981473 [TBL] [Abstract][Full Text] [Related]
17. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E; PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. Ventura JD; Nkolola JP; Chandrashekar A; Borducchi EN; Liu J; Mercado NB; Hope DL; Giffin VM; McMahan K; Geleziunas R; Murry JP; Yang Y; Lewis MG; Pau MG; Wegmann F; Schuitemaker H; Fray EJ; Kumar MR; Siliciano JD; Siliciano RF; Robb ML; Michael NL; Barouch DH NPJ Vaccines; 2022 May; 7(1):53. PubMed ID: 35585080 [TBL] [Abstract][Full Text] [Related]
19. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021 [TBL] [Abstract][Full Text] [Related]
20. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS; Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]